AnaptysBio, Inc. (ANAB) Downgraded by Zacks Investment Research
AnaptysBio, Inc. (NASDAQ:ANAB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
A number of other research analysts have also recently commented on ANAB. Robert W. Baird initiated coverage on AnaptysBio in a research note on Monday, July 10th. They set an “outperform” rating and a $36.00 target price on the stock. Credit Suisse Group upped their target price on AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 target price on shares of AnaptysBio in a research note on Tuesday, September 12th. Royal Bank Of Canada initiated coverage on AnaptysBio in a research note on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price on the stock. Finally, JMP Securities upped their target price on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $59.14.
Shares of AnaptysBio (NASDAQ ANAB) traded down 0.67% during midday trading on Wednesday, hitting $69.94. The stock had a trading volume of 1,201,177 shares. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $74.00. The company’s market cap is $1.42 billion. The company’s 50 day moving average is $35.88 and its 200 day moving average is $35.88.
AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $3.45 million. On average, analysts anticipate that AnaptysBio will post ($1.98) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “AnaptysBio, Inc. (ANAB) Downgraded by Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/11/anaptysbio-inc-anab-downgraded-by-zacks-investment-research.html.
In related news, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now owns 1,936,604 shares of the company’s stock, valued at $40,862,344.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,133,940 shares of company stock worth $24,223,316.
A number of large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in AnaptysBio in the first quarter worth approximately $24,474,000. Artal Group S.A. grew its stake in AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after purchasing an additional 205,310 shares in the last quarter. Marshall Wace North America L.P. bought a new position in AnaptysBio in the first quarter worth approximately $6,924,000. MARSHALL WACE ASIA Ltd bought a new position in AnaptysBio in the first quarter worth approximately $6,924,000. Finally, Vanguard Group Inc. grew its stake in AnaptysBio by 22.6% in the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after purchasing an additional 37,932 shares in the last quarter. 71.35% of the stock is currently owned by institutional investors.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.